Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1949 1
1954 1
1955 1
1961 1
1969 2
1972 1
1976 2
1985 3
1986 1
1987 2
1989 3
1990 3
1992 1
1993 3
1994 4
1995 5
1996 3
1997 1
1998 7
1999 6
2000 5
2001 14
2002 10
2003 4
2004 11
2005 11
2006 13
2007 12
2008 11
2009 9
2010 12
2011 13
2012 23
2013 17
2014 20
2015 22
2016 25
2017 24
2018 36
2019 29
2020 29
2021 43
2022 57
2023 58
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

538 results

Results by year

Filters applied: . Clear all
Page 1
Lecanemab in Early Alzheimer's Disease.
van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T. van Dyck CH, et al. Among authors: bateman rj. N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29. N Engl J Med. 2023. PMID: 36449413 Clinical Trial.
Alzheimer's disease.
Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Masters CL, et al. Among authors: bateman r. Nat Rev Dis Primers. 2015 Oct 15;1:15056. doi: 10.1038/nrdp.2015.56. Nat Rev Dis Primers. 2015. PMID: 27188934 Free article. Review.
Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study.
McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M, Koyama A, Irizarry M, Kramer LD, Bateman RJ. McDade E, et al. Among authors: bateman rj. Alzheimers Res Ther. 2022 Dec 21;14(1):191. doi: 10.1186/s13195-022-01124-2. Alzheimers Res Ther. 2022. PMID: 36544184 Free PMC article. Clinical Trial.
Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS.
Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barthélemy NR, Bateman RJ. Lucey BP, et al. Among authors: bateman rj. Ann Neurol. 2023 Jul;94(1):27-40. doi: 10.1002/ana.26641. Epub 2023 Apr 20. Ann Neurol. 2023. PMID: 36897120 Clinical Trial.
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S, Bali D, Ashton NJ, Barthélemy NR, Vanbrabant J, Stoops E, Vanmechelen E, He Y, Dolado AO, Triana-Baltzer G, Pontecorvo MJ, Zetterberg H, Kolb H, Vandijck M, Blennow K, Bateman RJ, Hansson O. Janelidze S, et al. Among authors: bateman rj. Brain. 2023 Apr 19;146(4):1592-1601. doi: 10.1093/brain/awac333. Brain. 2023. PMID: 36087307 Free PMC article.
Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid.
Drieu A, Du S, Storck SE, Rustenhoven J, Papadopoulos Z, Dykstra T, Zhong F, Kim K, Blackburn S, Mamuladze T, Harari O, Karch CM, Bateman RJ, Perrin R, Farlow M, Chhatwal J; Dominantly Inherited Alzheimer Network; Hu S, Randolph GJ, Smirnov I, Kipnis J. Drieu A, et al. Among authors: bateman rj. Nature. 2022 Nov;611(7936):585-593. doi: 10.1038/s41586-022-05397-3. Epub 2022 Nov 9. Nature. 2022. PMID: 36352225 Free PMC article.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.
Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. Dubois B, et al. Among authors: bateman r. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0. Lancet Neurol. 2014. PMID: 24849862
Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC; Dominantly Inherited Alzheimer Network. Bateman RJ, et al. N Engl J Med. 2012 Aug 30;367(9):795-804. doi: 10.1056/NEJMoa1202753. Epub 2012 Jul 11. N Engl J Med. 2012. PMID: 22784036 Free PMC article.
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques.
Li Y, Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Weiner MW, Shaw LM, Masters CL, Fowler CJ, Trojanowski JQ, Korecka M, Martins RN, Janelidze S, Hansson O, Bateman RJ. Li Y, et al. Among authors: bateman rj. Neurology. 2022 Feb 15;98(7):e688-e699. doi: 10.1212/WNL.0000000000013211. Epub 2021 Dec 14. Neurology. 2022. PMID: 34906975 Free PMC article.
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis.
Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, Fagan AM, Bateman RJ. Schindler SE, et al. Among authors: bateman rj. Neurology. 2019 Oct 22;93(17):e1647-e1659. doi: 10.1212/WNL.0000000000008081. Epub 2019 Aug 1. Neurology. 2019. PMID: 31371569 Free PMC article.
538 results